To confirm that cross-priming had occurred, naïve HLA-A*0201+ CD8+ T cells were exposed to three stimulations with autologous HLA-A*0201+ DCs loaded with HLA-A*0201- breast cancer cell lines T47D or Hs578T and tested on HLA-A*0201+ MCF-7 target cells in a 4-hour 51Cr release assay (Figure 3a and 3b) and a 24-hour tumor inhibition assay [24] (Figure 3c). The gene discussed is CD8A; the disease is breast cancer.